Serum Bupivacaine Concentration Levels After Injection of Liposomal Bupivacaine Into the Knee
1 other identifier
observational
40
1 country
1
Brief Summary
Serum levels of bupivacaine over time after peri-articular injection of a mixture of liposomal bupivacaine and plain bupivacaine during total knee arthroplasty.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Nov 2015
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 1, 2015
CompletedFirst Submitted
Initial submission to the registry
December 7, 2015
CompletedFirst Posted
Study publicly available on registry
December 10, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2016
CompletedDecember 9, 2016
December 1, 2016
1 year
December 7, 2015
December 8, 2016
Conditions
Outcome Measures
Primary Outcomes (1)
Serum Bupivacaine levels
5 minutes to 24 hours after injection
Interventions
Injection of a mixture of liposomal and plain bupivacaine around the knee during total knee arthroplasty.
Eligibility Criteria
Adults of at least 18 years of age having a primary, unilateral total knee arthroplasty with a surgical plan to have an intra-articular injection of a mixture of 266 mg of Exparel, 125 mg of bupivacaine, 1:300,000 epinephrine, and 0.9% saline to make a total volume of 100 ml.
You may qualify if:
- Adults of at least 18 years of age having a primary, unilateral total knee arthroplasty with a surgical plan to have an intra-articular injection of a mixture of 266 mg of Exparel, 125 mg of bupivacaine, 1:300,000 epinephrine, and 0.9% saline to make a total volume of 100 ml.
You may not qualify if:
- Known hepatic dysfunction or renal insufficiency (creatinine \> 1.5 mg/dL);
- allergy to the study medications;
- pregnancy;
- incarceration;
- inability to communicate with the investigators;
- morbid obesity (body mass index \> 40 kg/m2).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Uutah
Salt Lake City, Utah, 84132, United States
Related Publications (1)
Buys MJ, Murphy MF, Warrick CM, Pace NL, Gililland JM, Pelt CE, Bankhead BR, Patzkowsky JL, Johnson KB. Serum Bupivacaine Concentration After Periarticular Injection With a Mixture of Liposomal Bupivacaine and Bupivacaine HCl During Total Knee Arthroplasty. Reg Anesth Pain Med. 2017 Sep/Oct;42(5):582-587. doi: 10.1097/AAP.0000000000000636.
PMID: 28727583DERIVED
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Professor
Study Record Dates
First Submitted
December 7, 2015
First Posted
December 10, 2015
Study Start
November 1, 2015
Primary Completion
November 1, 2016
Study Completion
November 1, 2016
Last Updated
December 9, 2016
Record last verified: 2016-12
Data Sharing
- IPD Sharing
- Will not share